COMPANY NEWS

NEWS  |  03.08.2021

Fierce Pharma Logo.jpg

As viral vector demand surges, CDMO Matica establishes a beachhead in Texas

A lack of global capacity to produce cell and gene therapies has been exacerbated by an even more pressing need: to develop and manufacture coronavirus vaccines. So it appears the timing is right for Matica Biotechnology, a developer and producer of viral vectors, to put down roots in the United States.

The brand-new CDMO has teamed up with Texas A&M University and its advanced manufacturing center and started work on a 25,000 square-foot viral vector plant near the university's College Station campus.

NEWS  |  03.03.2021

collaboration logo (JPG) - website.jpg

Matica Biotechnology, Inc. Announces

Master Research Agreement with Texas A&M

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a master research agreement with the Center for Innovation in Advanced Development and Manufacturing (CIADM) at Texas A&M University Health Science Center (TAMHSC).  The agreement covers joint research and development projects for plasmid, protein and viral vector products in compliance with FDA regulations.

NEWS  |  02.23.2021

Matica Biotechnology, Inc. Announces

Groundbreaking for a New GMP Facility

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located in Providence Park at 2501 Earl Rudder Freeway in College Station.

NEWS  |  12.15.2020

Matica Biotechnology, Inc. Announces Plans to Construct GMP Facility for Viral Vector Production

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for the location of its GMP production facility located in College Station, TX. Construction of the 25,000 ft 2 facility will commence in Q4 2020 and is dedicated to the production of viral vectors used in cell and gene therapies, vaccines and oncolytic products. When completed, the facility will provide Matica Bio’s clients with comprehensive viral vector development, manufacturing and analytical services centrally located in one of the fastest-growing biotech regions in the United States.

NEWS  |  06.18.2020

CHA Biotech to Raise $62 mn to Bolster CDMO Business

CHA Biotech aims to raise a total of 75 billion won ($62 million) through issuances of bonds with option to equity swap to strengthen contract development and manufacturing servicing for global gene therapy developers, the Korean stem cell research company said in a regulatory filing on Wednesday.

Let's Get To Work!

Contact Matica Bio now to request a quote and discuss your virus production needs with one of our experts. Understanding vector type, timelines and budgets early in the process will help to formulate a winning manufacturing strategy. Contact us today!

ADDRESS

Matica Biotechnology, Inc.

2501 Earl Rudder Freeway, 

College Station, TX

PHONE

+1 979-321-7500

EMAIL

© 2021 by Matica Biotechnology Inc.

Contact Us

Gray 190906_Matica Biotechnology CI desi

YOUR CDMO FOR

CELL & GENE THERAPIES

ADVANCED THERAPEIS